Mitsubishi Tanabe Pharma makes proprietary prescription pharmaceuticals in a number of therapeutic areas, including cardiovascular disease, diabetes, neuroscience, immunology, and oncology. In its home market, it sells products such as anticoagulant Anplag, anti-allergy medicine Talion, liver drug Urso, and neuroprotective agent Radicut. Its Benesis unit makes therapeutic plasma proteins such as albumin. The company markets and sells its products through in-house sales agents and distributors. Formerly Mitsubishi Pharma, the company merged with fellow Japanese drugmaker Tanabe Seiyaku and subsequently changed its name; Mitsubishi Chemical Holdings owns a majority stake in the new entity.

NPS Pharmaceuticals, Inc. company was founded in 1986 and is headquartered in Bedminster, New Jersey. NPS Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of specialty therapeutics for gastrointestinal and endocrine disorders. The company is advancing two late-stage programs to restore or replace biological function, including GATTEX (teduglutide), which is in Phase 3 clinical development for parenteral dependent short bowel syndrome; and NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection) that is in Phase 3 clinical development as a hormone therapy for hypoparathyroidism. It complements its internal programs with strategic partnerships with Amgen, GlaxoSmithKline, Kyowa Kirin, and Nycomed.

Eurand N.V. company was formerly known as Eurand B.V. Eurand N.V. was incorporated in 1984 and is based in Amsterdam, the Netherlands. Eurand N.V., a specialty pharmaceutical company, develops, manufactures, and commercializes pharmaceutical and biopharmaceutical products. The company develops these products based on its proprietary customized release technologies used to reduce daily dosing requirements and time the release of drugs in the body to increase efficacy or to reduce side effects; Tastemasking/ODTs technologies to increase patient compliance through more convenient dosage forms, such as orally disintegrating tablets and taste-masked drugs; bioavailability enhancement technologies to improve drug absorption; and drug conjugation technologies to extend drug half-life and to target specific organs or other biological targets, such as tumors. Its technologies are used for applications in drug products used for various therapeutic areas, including cardiovascular, gastrointestinal, pain, nutrition, and respiratory.Eurand company offers EUR-1037, as an over-the-counter sleep-aid; EUR-1025, an oral formulation of ondansetron, an anti-emetic prescribed to prevent nausea and vomiting; and EUR-1073, an enteric coated, controlled release formulation of beclomethasone diproprionate for the treatment of inflammatory bowel disease. It products also include Zentase, also known as EUR-1008, a porcine-derived proprietary enzyme replacement product for the treatment of exocrine pancreatic insufficiency, which has completed Phase III clinical trials; Amrix, a sustained release formulation of cyclobenzaprine hydrochloride, used as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute and painful musculoskeletal conditions; and products and services to the cystic fibrosis community.

IntelliPharmaCeutics International (IPC) is getting smarter about drug delivery by the second. The pharmaceutical company uses its controlled release drug delivery technology to develop new and generic drug products for enhanced treatment of pain, cardiovascular, and neurological issues. Its products are based on its patented HYPERMATRIX platform, which controls a drug's release time within the gastrointestinal tract. With a diverse pipeline, IPC develops its own proprietary products, as well as ones for third parties, including international clients; it also offers contract manufacturing. In 2009 the formerly private company merged with Vasogen to create the publicly traded IntelliPharmaCeutics International.

Teikoku Pharma USA is a wholly-owned subsidiary of Teikoku Seiyaku Inc., a specialty pharmaceutical company that develops, and manufactures enhanced pharmaceutical products based on its transdermal drug delivery technologies. Teikoku focuses its efforts in two therapeutic areas; Pain and CNS. By applying our transdermal technologies to existing actives or co-developing new formulations, Teikoku helps pharmaceutical companies extend patent protections, diversify product lines, provide better delivery mechanisms, and promote brand loyalty. Teikoku charts new territory in prescription, OTC, and medical device markets around the world, transforming ideas into ideally delivered products that carry a competitive edge in quality and innovation.

Collegium Pharmaceutical's wisdom is in developing over-the-counter and prescription drugs for a variety of conditions affecting the skin and central nervous and respiratory systems. Typically the company starts with existing drugs and works to improve them through new delivery systems that modify their release, or prevent abuse. It is working with drugs to treat such conditions as fibromyalgia, pain, and sleep apnea. Through its subsidiary Onset Therapeutics, the company markets wound care and dermatology (acne, skin infections) drugs. Its topical aerosol product Exactacain is licensed and sold by Healthpoint while its approved allergy nasal spray AllerNaze is licensed to Lupin Ltd.

DOV Pharmaceutical, Inc. is a biopharmaceutical company focused on the development of product candidates for disorders of the central nervous system (CNS). The Company has drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The Company also has a drug development program subject to regulatory review, Indiplon, which is being developed as a treatment for insomnia. The Company has sublicensing agreements for the development and commercialization of certain product candidates with XTL Biopharmaceuticals, Inc. (XTL) for bicifadine, with Blue Note Pharmaceuticals, Inc. (Blue Note) for DOV diltiazem, and with Neurocrine Biosciences, Inc. (Neurocrine) for indiplon.

Biovail Corporation company was founded in 1983 and is headquartered in Mississauga, Canada. Biovail Corporation, a pharmaceutical company, engages in the formulation, clinical testing, registration, manufacture, and commercialization of pharmaceutical products principally in the United States and Canada. The company focuses on central nervous system disorders, pain management, and cardiovascular diseases. Its products include Xenazine for the treatment of chorea associated with Huntington's disease; Wellbutrin XL for the treatment of depression in adults; Ultram ER for the management of chronic pain in adults; Zovirax Ointment for the management of initial genital herpes; Zovirax Cream for the treatment of herpes labialis; and Cardizem LA that provides blood pressure control.Biovail Corporation company also provides Tiazac/Tiazac XC for the treatment of hypertension and angina; Wellbutrin SR for the treatment of depression; Zyban for smoking cessation treatment; Monocor for the treatment of hypertension and congestive heart failure; Retavase, a tissue plasminogen activator used in thrombolytic therapy; Glumetza to control hyperglycemia in adult patients with non-insulin dependent and mature onset diabetes; Ralivia for the management of pain; and Nitoman for the treatment of hyperkinetic movement disorders, such as Huntington's chorea, Hemiballismus, Senile Chorea, Tic and Gilles de la Tourette Syndrome, and Tardive Dyskinesia. Its legacy products comprise Cardizem CD medications in the calcium channel blocker category of cardiovascular drugs; Ativan for the management of anxiety disorders; and Isordil to treat prophylaxis of ischemic heart pain associated with coronary insufficiency. The company's generic products consist of bioequivalent formulations of Cardizem CD, Adalat CC, Procardia XL, Tiazac, Voltaren XR, and Trental. In addition, it offers research, development, and clinical contract research services to third parties.

OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of cancer. The company's lead candidate, OGX-011, is being evaluated in five Phase II clinical trials. OGX-011, which is also known as custirsen sodium, inhibits the production of clusterin, a protein that is over-produced in various types of cancer and in response to a range of cancer treatments, including hormone ablation therapy, chemotherapy, and radiation therapy. Its other product candidates include OGX-427, a Phase 1 clinical trial product, which is focused on reducing heat shock protein 27; and SN2310, a phase I clinical trial completed product for the treatment of cancer. The company's preclinical stage products consist of OGX-225, an inhibitor of insulin growth factor binding proteins 2 and 5; and CSP-9222, a compound from a family of caspase activators. OncoGenex Pharmaceuticals is based in Bothell, Washington.

Roche Colorado is one of the research, development, and manufacturing facilities of pharmaceutical giant Roche. Its R&D operations focus on developing efficient and high-quality production processes for manufacturing pharmaceutical ingredients and compounds. It has worked to bring to market such drugs as the anti-HIV treatments Fuzeon and Invirase and the influenza drug Tamiflu. Roche Colorado company also provides contract manufacturing of peptides, a protein-like compound used in pharmaceuticals. Roche Colorado is one of several US-based research and production facilities owned by Roche; affiliates include Hoffman-La Roche and Genentech.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.